CRISPR Therapeutics (NASDAQ:CRSP) Now Covered by Bryan, Garnier & Co

Analysts at Bryan, Garnier & Co started coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) in a report issued on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Bryan, Garnier & Co’s price target would indicate a potential upside of 53.04% from the stock’s current price.

CRSP has been the subject of a number of other research reports. Citigroup cut their price target on shares of CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating for the company in a research note on Wednesday, November 23rd. Chardan Capital cut their target price on shares of CRISPR Therapeutics from $153.00 to $123.00 and set a “buy” rating for the company in a research note on Wednesday, February 22nd. Oppenheimer cut their target price on shares of CRISPR Therapeutics from $110.00 to $102.00 and set an “outperform” rating for the company in a research note on Thursday, February 23rd. Credit Suisse Group cut their target price on shares of CRISPR Therapeutics from $78.00 to $65.00 and set a “neutral” rating for the company in a research note on Wednesday, February 22nd. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Wednesday, February 22nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $74.59.

CRISPR Therapeutics Trading Up 0.8 %

CRISPR Therapeutics stock opened at $45.74 on Friday. The company has a market cap of $3.60 billion, a P/E ratio of -5.46 and a beta of 1.73. CRISPR Therapeutics has a 1-year low of $38.94 and a 1-year high of $86.95. The company has a fifty day simple moving average of $49.78 and a 200 day simple moving average of $53.71.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its earnings results on Tuesday, February 21st. The company reported ($1.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.27) by $0.86. The business had revenue of $6.00 million during the quarter, compared to the consensus estimate of $7.37 million. CRISPR Therapeutics had a negative net margin of 54,271.70% and a negative return on equity of 31.85%. The firm’s revenue for the quarter was down 53.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.84) earnings per share. On average, equities research analysts forecast that CRISPR Therapeutics will post -7.54 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction dated Friday, January 27th. The shares were sold at an average price of $51.47, for a total value of $1,286,750.00. Following the transaction, the chief executive officer now directly owns 369,111 shares of the company’s stock, valued at approximately $18,998,143.17. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 75,000 shares of company stock valued at $3,516,250 in the last ninety days. 5.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Fairfield Bush & CO. bought a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $90,000. Bank of New York Mellon Corp grew its holdings in shares of CRISPR Therapeutics by 40.7% during the 1st quarter. Bank of New York Mellon Corp now owns 91,062 shares of the company’s stock valued at $5,716,000 after purchasing an additional 26,358 shares during the last quarter. US Bancorp DE grew its holdings in shares of CRISPR Therapeutics by 10.0% during the 1st quarter. US Bancorp DE now owns 9,526 shares of the company’s stock valued at $598,000 after purchasing an additional 866 shares during the last quarter. BlackRock Inc. grew its holdings in shares of CRISPR Therapeutics by 79.2% during the 1st quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock valued at $143,038,000 after purchasing an additional 1,007,246 shares during the last quarter. Finally, Cibc World Market Inc. grew its holdings in shares of CRISPR Therapeutics by 49.3% during the 1st quarter. Cibc World Market Inc. now owns 8,354 shares of the company’s stock valued at $524,000 after purchasing an additional 2,760 shares during the last quarter. 71.51% of the stock is owned by institutional investors.

About CRISPR Therapeutics

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.